Establishment of a novel diagnosis and treatment system of prostate cancer for both early continence recovery and cancer control after radical prostatectomy.

Establishment of a novel diagnosis and treatment system of prostate cancer for both early continence recovery and cancer control after radical prostatectomy. - Establishment of a novel diagnosis and treatment system of prostate cancer for both early continence recovery and cancer control after radical prostatectomy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000043978

Enrollment

Registered

2021-08-01

Start date

2021-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Robot-assisted radical prostatectomy for localized prostate cancer

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Prostate cancer diagnosed by MRI-US fusion target biopsy and systematic 12-core biopsy. 2. Patients whose PSA level are under 20ng/mL. 3. Patients who are not diagnosed as extra prostatic extent by mpMRI. 4. Patients who are not detected more than Gleason score 3+3 in prostate apex. 5. Patients who are not ditected more than Gleason score 4+3 in biopsy specimens.

Exclusion criteria

Exclusion criteria: Gleason score 4+4

Design outcomes

Primary

Measure	Time frame
1. Oncological outcomes 2. early continence recovery	—

Countries

Japan

Contacts

Public ContactKent Kanao

Saitama Medical University International Medical Center Uro-Oncology

kanaok@saitama-med.ac.jp042-984-4111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026